Search

The article is devoted to the latest achievements in the field of research, development, and implementation of various types of medicinal products based on recombinant probiotics. The benefits of probiotics, their modern use in medicine along with the most frequently used genera and species of probiotic microorganisms were highlighted. The medicinal and therapeutic activities of the studied probiotics were indicated. The review suggests various methods of creating recombinant probiotic microorganisms, including standard genetic engineering methods, as well as systems biology approaches and new methods of using the CRISPR-Cas system. The range of potential therapeutic applications of drugs based on recombinant probiotics was proposed. Special attention was paid to modern research on the creation of new, more effective recombinant probiotics that can be used for various therapeutic purposes. Considering the vast diversity of therapeutic applications of recombinant probiotics and ambiguous functions, their use for the potential treatment of various common human diseases (non-infectious and infectious diseases of the gastrointestinal tract, metabolic disorders, and allergic conditions) was investigated. The prospects for creating different types of vaccines based on recombinant probiotics together with the prospects for their implementation into medicine were considered. The possibilities of using recombinant probiotics in veterinary medicine, particularly for the prevention of domestic animal diseases, were reviewed. The prospects for the implementation of recombinant probiotics as vaccines and diagnostic tools for testing certain diseases as well as modeling the work of the human digestive system were highlighted. The risks of creation, application, including the issues related to the regulatory sphere regarding the use of new recombinant microorganisms, which can potentially enter the environment and cause unforeseen circumstances, were outlined.

To detect and prevent emerging epidemics, discovery platforms are urgently needed, for the rapid development of diagnostic assays. Molecular diagnostic tests for COVID-19 were developed shortly after the isolation of SARS-CoV-2. However, serological tests based on antiviral antibody detection, revealing previous exposure to the virus, required longer testing phases, due to the need to obtain correctly folded and glycosylated antigens. The delay between the identification of a new virus and the development of reliable serodiagnostic tools limits our readiness to tackle future epidemics. We suggest that the protozoan Leishmania tarentolae can be used as an easy-to-handle microfactory for the rapid production of viral antigens to face emerging epidemics. We engineered L. tarentolae to express the SARS-CoV-2 receptor-binding domain (RBD) and we recorded the ability of the purified RBD antigen to detect SARS-CoV-2 infection in human sera, with a sensitivity and reproducibility comparable to that of a reference antigen produced in human cells. This is the first application of an antigen produced in L. tarentolae for the serodiagnosis of a Coronaviridae infection. On the basis of our results, we propose L. tarentolae as an effective system for viral antigen production, even in countries that lack high-technology cell factories. [ABSTRACT FROM AUTHOR]

To detect and prevent emerging epidemics, discovery platforms are urgently needed, for the rapid development of diagnostic assays. Molecular diagnostic tests for COVID-19 were developed shortly after the isolation of SARS-CoV-2. However, serological tests based on antiviral antibody detection, revealing previous exposure to the virus, required longer testing phases, due to the need to obtain correctly folded and glycosylated antigens. The delay between the identification of a new virus and the development of reliable serodiagnostic tools limits our readiness to tackle future epidemics. We suggest that the protozoan Leishmania tarentolae can be used as an easy-to-handle microfactory for the rapid production of viral antigens to face emerging epidemics. We engineered L. tarentolae to express the SARS-CoV-2 receptor-binding domain (RBD) and we recorded the ability of the purified RBD antigen to detect SARS-CoV-2 infection in human sera, with a sensitivity and reproducibility comparable to that of a reference antigen produced in human cells. This is the first application of an antigen produced in L. tarentolae for the serodiagnosis of a Coronaviridae infection. On the basis of our results, we propose L. tarentolae as an effective system for viral antigen production, even in countries that lack high-technology cell factories.

Fats and lipids have always had a primary role in the history of humankind, from ancient civilisations to the modern and contemporary time, going from domestic and cosmetic uses, to the first medical applications and later to the large-scale industrial uses for food, pharmaceutical, cosmetics, and biofuel production. Sources and uses of those have changed during time following the development of chemical sciences and industrial technological advances. Plants, fish, and animal fats have represented the primary source of lipids and fats for century. Nowadays, the use of fatty acid sources has taken a turn: industries are mainly interested in polyunsaturated fatty acids (PUFAs), which have beneficial properties in human health; and also, for high-value fatty acids product for innovative and green production of biofuel and feedstocks. Thus, the constant increase in demand of fatty acids, the fact that marine and vegetable sources are not adequate to meet the high level of fatty acids required worldwide and climate change, have determined the necessity of the search for renewable and sustainable sources for fatty acids. Biotechnological advances and bioengineering have started looking at the genetic modification of algae, bacteria, yeasts, seeds, and plants to develop cell factory able to produce high value fatty acid products in a renewable and sustainable manner. This innovative approach applied to FA industry is a peculiar example of how biotechnology can serve as a powerful mean to drive the production of high value fatty acid derivatives on the concept of circular bioeconomy, based on the reutilisation of organic resources for alternative and sustainable productive patterns that are environmentally friendly.

This is a comprehensive review, with 114 references, of the chemical diversity found in the fungus Penicillium roqueforti. Secondary metabolites of an alkaloidal nature are described, for example, ergot alkaloids such as festuclavine, isofumigaclavines A and B, and diketopiperazine alkaloids such as roquefortines A-D, which are derived from imidazole. Other metabolites are marcfortines A-C, PR-toxin, eremofortines A-E, mycophenolic and penicillic acids, and some γ-lactones. Also, recent developments related to the structural characteristics of botryodiplodin and andrastin are studied-the latter has anticancer properties. Finally, we discuss the enzymes of P. roqueforti, which can participate in the biotechnological production of high value-added molecules, as well as the use of secondary metabolite profiles for taxonomic purposes. [ABSTRACT FROM AUTHOR]

• A new generation cell factory (CF) of non-engineered S. cerevisiae for cellobiose fermentation. • The two bioreactors for cellobiose fermentation are substituted with one. • The CF design conceptual character due to its application in white biotechnology bioprocessing. • CF substitution of S. cerevisiae by a microorganism for production of another chemical using cellobiose. • Future investigation to increase yield as increase of cellobiose concentration leads to reduced yield. The aim of this work was to ferment cellobiose to fuel-grade ethanol in one-step bioconversion employing a cell-factory (CF) of non-Genetically Modified Organism (non-GMO) Saccharomyces cerevisiae. The proposed technology involved the production of a freeze-dried preparation of CF of non-GMO S. cerevisiae covered by a layer of starch-gel (SG) containing cellulase enzyme. Parameters studied for one-step bioconversion of cellobiose to ethanol included temperature (33–40 °C), cellobiose concentration (70–150 g/L), and cellulase activity (60–150 FPU/g). High conversion (90%) of cellobiose in a 48 h one-step process was achieved using 70 g/L cellobiose, 150 FPU/g at 30 °C, indicating the efficiency of CF. S. cerevisiae in CF were also capable to ferment at 40 °C with the major role of enzyme activity and cellobiose concentration in fermentation. In our studies, the ethanol yield and conversion of cellobiose were found competitive, with other processes reported with S. cerevisiae as GMO and enzyme co-immobilized in alginates beads. Consequently, the results revealed a new concept for bio-ethanol production from cellobiose in one-step simultaneous-hydrolysis-fermentation (OSHF), which could be a precursor study for large-scale cellulose bioconversion for fuel-grade alcohol production. [ABSTRACT FROM AUTHOR]

Abstract: Interest in renewable and clean energies such as hydrogen has increased because of the high level of polluting emissions, increasing costs associated with petroleum and the escalating problems of global climate change. In the presence of a light source, a microbial photosynthetic process provides a system for the conversion of some organic compounds into biomass and hydrogen. Using Rhodopseudomonas palustris as a cell-factory, hydrogen photo-evolution was investigated in a photobioreactor (PBR) irradiated either from one or two opposite sides. Irradiating the photobioreactor from only one side, in the presence of malic acid, a reactor hydrogen production of 2.786l(H2) PBR−1 was achieved. When the PBR was irradiated from two opposite sides, hydrogen photo-evolution increased to 3.162l(H2) PBR−1. Experiments were carried out using inoculum from either the retardation or the exponential growth phases. Using the latter, the highest hydrogen photo-evolution rate based on the bacteriochlorophyll (Bchl) concentration was achieved (3295μl(H2)mg (Bchl−1 h−1). The hydrogen to biomass ratio (r g) was 1.91lg−1 in the medium containing malic acid and 1.07lg−1 in that containing acetic acid. It was found that the hydrogen production rate was higher with malic than with acetic acid. Although photobiological hydrogen production cannot furnish alone the greater and greater world requirements of clean renewable energy, it is desirable that photobiological hydrogen technology will grow, in the near future, because photobioreactors for bio-hydrogen production can be positioned in fringe areas without competition with agricultural lands. [Copyright &y& Elsevier]

• Preparation of a new generation cell factory of non-genetically modified S. cerevisiae without genetic modification for lactose and whey conversion in one batch. • Both cell factories of two-layers and of covering cells using SG for lactose fermentation in one-batch were produced successfully. • Freeze dried cell factories lead to improved results as compared with non freeze dried. • Both cell factories can be considered as models for white biotechnology using cheap available raw by-product materials containing lactose. The objective of this project was to ferment lactose and whey to ethanol in one-step process. Models of cell factory of non-engineered S.cerevisiae have been proposed to ferment lactose. The cell factory of non-engineered S. cerevisiae/SG-lactase was prepared by the addition, of a starch gel solution containing lactase on non-engineered S. cerevisiae, and freeze drying of it. The 2-layer non engineered S.cerevisiae -TC/SG-lactase factory was prepared by immobilizing S. cerevisiae on the internal layer of tubular cellulose (TC), and the lactase enzyme was contained in the upper layer of starch gel (SG) covering cells of S. cerevisiae. Using such cell factory for the fermentation of lactose, alcohol yield of 23-32 mL/L at lactose conversion of 71-100%. The improvement in alcohol yield by cell factory versus co-immobilization of lactase enzyme and S. cerevisiae on alginates, was found in the range of 28-78%. Likewise, the cell factories are more effective than engineered S. cerevisiae. The fermentation of whey instead of lactose resulted in a significant reduction of the fermentation time. Freeze-dried cell factories led to improved results as compared with non-freeze dried. When lactase was substituted with L. casei , ethanol and lactic acid were produced simultaneously at high concentrations, but in a much longer fermentation time. The cell factories can be considered as models for white biotechnology using lactose containing raw materials. This suggested cell factory model can be applied for other bioconversions using the appropriate enzymes and cells, in the frame of White Biotechnology without genetic modification. [ABSTRACT FROM AUTHOR]

Fats and lipids have always had a primary role in the history of humankind, from ancient civilisations to the modern and contemporary time, going from domestic and cosmetic uses, to the first medical applications and later to the large-scale industrial uses for food, pharmaceutical, cosmetics, and biofuel production. Sources and uses of those have changed during time following the development of chemical sciences and industrial technological advances. Plants, fish, and animal fats have represented the primary source of lipids and fats for century. Nowadays, the use of fatty acid sources has taken a turn: industries are mainly interested in polyunsaturated fatty acids (PUFAs), which have beneficial properties in human health; and also, for high-value fatty acids product for innovative and green production of biofuel and feedstocks. Thus, the constant increase in demand of fatty acids, the fact that marine and vegetable sources are not adequate to meet the high level of fatty acids required worldwide and climate change, have determined the necessity of the search for renewable and sustainable sources for fatty acids. Biotechnological advances and bioengineering have started looking at the genetic modification of algae, bacteria, yeasts, seeds, and plants to develop cell factory able to produce high value fatty acid products in a renewable and sustainable manner. This innovative approach applied to FA industry is a peculiar example of how biotechnology can serve as a powerful mean to drive the production of high value fatty acid derivatives on the concept of circular bioeconomy, based on the reutilisation of organic resources for alternative and sustainable productive patterns that are environmentally friendly., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Cerone and Smith.)